BBNX Quote, Financials, Valuation and Earnings

InspireMD, Inc. has a net margin of -52.14% compared to Beta Bionics, Inc.'s net margin of -503.69%. Beta Bionics, Inc.'s return on equity of -38.19% beat InspireMD, Inc.'s return on equity of -121.49%.

Beta Bionics, Inc. has a consensus price target of $31.30, signalling upside risk potential of 6.54%. On the other hand InspireMD, Inc. has an analysts' consensus of $4.50 which suggests that it could grow by 139.36%. Given that InspireMD, Inc. has higher upside potential than Beta Bionics, Inc., analysts believe InspireMD, Inc. is more attractive than Beta Bionics, Inc..

Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InspireMD, Inc. has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.446%.

Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InspireMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. InspireMD, Inc. pays out -- of its earnings as a dividend.

Beta Bionics, Inc. quarterly revenues are $27.3M, which are larger than InspireMD, Inc. quarterly revenues of $2.5M. Beta Bionics, Inc.'s net income of -$14.2M is lower than InspireMD, Inc.'s net income of -$12.7M. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while InspireMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 14.41x versus 13.49x for InspireMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -52.14% compared to Beta Bionics, Inc.'s net margin of -862.39%. Beta Bionics, Inc.'s return on equity of -38.19% beat VolitionRX Ltd.'s return on equity of --.

Beta Bionics, Inc. has a consensus price target of $31.30, signalling upside risk potential of 6.54%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Beta Bionics, Inc., analysts believe VolitionRX Ltd. is more attractive than Beta Bionics, Inc..

Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Beta Bionics, Inc. quarterly revenues are $27.3M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Beta Bionics, Inc.'s net income of -$14.2M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 14.41x versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of -52.14% compared to Beta Bionics, Inc.'s net margin of -1037.17%. Beta Bionics, Inc.'s return on equity of -38.19% beat Catheter Precision, Inc.'s return on equity of -192.05%.

Beta Bionics, Inc. has a consensus price target of $31.30, signalling upside risk potential of 6.54%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1496.69%. Given that Catheter Precision, Inc. has higher upside potential than Beta Bionics, Inc., analysts believe Catheter Precision, Inc. is more attractive than Beta Bionics, Inc..

Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

Beta Bionics, Inc. quarterly revenues are $27.3M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Beta Bionics, Inc.'s net income of -$14.2M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 14.41x versus 11.19x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -52.14% compared to Beta Bionics, Inc.'s net margin of 3.93%. Beta Bionics, Inc.'s return on equity of -38.19% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Beta Bionics, Inc. has a consensus price target of $31.30, signalling upside risk potential of 6.54%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Beta Bionics, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Beta Bionics, Inc..

Beta Bionics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Beta Bionics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beta Bionics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Beta Bionics, Inc. quarterly revenues are $27.3M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Beta Bionics, Inc.'s net income of -$14.2M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Beta Bionics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beta Bionics, Inc. is 14.41x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.